Soligenix Featured in Seeking Alpha as “Strong Buy”
With a “strong buy” recommendation, Soligenix (Nasdaq: SNGX) enjoyed a notable feature today in Seeking Alpha, a site that empowers investors “to make the absolute best investing decisions by leveraging our independent and balanced stock research, fundamental analysis tools, crowdsourced debate, reliable news and actionable market data.”
The late-stage biopharma, now trading at a $20 million market cap, was hailed as it prepares to file for an NDA for HyBryte, which may become the first-in-class treatment for cutaneous T-cell lymphoma. The review highlights Soligenix’ plans to commercialize HyBryte in the United States as a specialized market with a sound referral base as well as low barriers to access and high likelihood of reimbursement.
In addition, Soligenix recently received a U.S. patent allowance for its vaccine platform, which continues to show success against some of the greatest viral threats across the globe. With strong interest from government and defense organizations, the vaccine platform is also a good fit with President Biden’s pandemic-preparedness initiative, and the article posits that these reasons alone are cause for celebration.
Both business segments—and their latest positive results—were featured as reasons for the “strong buy” rating.
Author E. Roudasev wrote that the “company is a very strong buy for me given HyBryte’s room for commercial growth” as well as the strength of its public health platform, adding that HyBryte “holds the potential of a +$500 million valuation in the years to come.” The article also notes that the ThermoVax platform for developing heat-stable vaccines continues to generate “strong and consistent results” across viral categories.
The Seeking Alpha article concluded that, “That leads the company to now have a de-risked and approval-ready main asset, with some pretty interesting additional vaccine developments in the pipeline. I believe there is a significant upward opportunity for long investors here.”